Pfizer Stock (NYSE:PFE)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$26.02

52W Range

$24.48 - $31.54

50D Avg

$28.71

200D Avg

$28.16

Market Cap

$140.54B

Avg Vol (3M)

$33.66M

Beta

0.61

Div Yield

$1.68 (6.77%)

PFE Company Profile


Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

88,000

IPO Date

Jun 01, 1972

Website

PFE Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Biopharma Segment$57.19B$98.99B-
Comirnaty-$3.10B-
Total Alliance Biopharmaceuticals-$8.54B$7.65B
Total Sterile Injectable Pharmaceuticals--$5.75B
Total Biosimilars--$2.34B

Fiscal year ends in Dec 23 | Currency in USD

PFE Financial Summary


Dec 23Dec 22Dec 21
Revenue$58.50B$100.33B$81.29B
Operating Income$8.09B$40.03B$24.83B
Net Income$2.12B$31.37B$21.98B
EBITDA$2.17B$43.64B$28.53B
Basic EPS$0.37$5.59$3.92
Diluted EPS$0.37$5.47$3.85

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 29, 24 | 5:16 PM
Q2 24Jul 30, 24 | 2:26 PM
Q1 24May 01, 24 | 12:00 AM

Peer Comparison


TickerCompany
LLYEli Lilly and Company
ABBVAbbVie Inc.
MRKMerck & Co., Inc.
AMGNAmgen Inc.
JNJJohnson & Johnson
BMYBristol-Myers Squibb Company
GILDGilead Sciences, Inc.